It was recently discovered that if hormone therapy (ADT) is added to radiation cancer deaths are lowered by nearly 50 % in men with locally advanced prostate cancer aged 76 to 85 compared to men who only received hormone therapy. Prior studies have shown that 40% of men with aggressive prostate cancers are treated with [...]
There was a recent Norwegian study which reviewed the impact of salvage external beam radiotherapy (EBRT) on post-prostatectomy patients. They evaluated long-term follow-up on biochemical-free recurrence (PSA only recurrence) (BFR) and metastatic-free survival. He study also described the pathological and clinical predictors of outcome. The study was conducted between 1987–2010. It included 76 men with [...]
A small study from one hospital in Norway has suggested that PSA doubling times after surgery may predict the value of salvage radiation therapy alone as a second line form of therapy. Servoll et al carried out a small retrospective analysis of data derived from 76 men treated by salvage external beam radiation therapy (EBRT) [...]
A Small study suggests that alternating testosterone levels may make hormonal therapy work longer A recent very small study was published that might lend a new light on hormone therapy for advanced prostate cancer, Bipolar ADT. This study suggests that a new treatment strategy might be effective where men alternate between low and high levels [...]
Normally I don't write about pre-clinical things unless they are particularly interesting. You guessed it; I found a preclinical item that is interesting. According to a recent published study by Richard Pestell, M.D., Ph.D., MBA, Director of the Sidney Kimmel Cancer Center at Thomas Jefferson University the receptor CCR5, which is targeted by already approved [...]
On December 7, 2014 the TV show 60 Minutes (CBS) aired a very interesting story (narrated by Dr. Sanjay Gupta) interview about an amazing sounding man, Dr. Patrick Soon-Shing. To describe him as a genius would be an unfair understatement. Dr. Soon-Shing is a billionaire who has already invested about $1 billion dollars of his [...]
There has been much conversation surrounding the use of intermittent androgen deprivation (IAD) as opposed to continuous androgen deprivation (CAD) in men with prostate cancer who need hormone therapy (ADT). The question that has been at issue is if either method is superior to the other. There have been studies that have concluded that they [...]
There are a number of different flavors of hormone therapy (ADT) used to treat advanced prostate cancer. However, they could be summed up and put into two different categories. 1- The use of luteinizing hormone-releasing hormone (LHRH) agonist therapy (drugs like Lupron and Zoladex) along with short term antiandrogen (AA) flare protection 2- Degarelix, a [...]
Sometimes scientific research is amazing! We are so lucky to have so many brilliant and gifted young people interested in conquering cancer. One of these brilliant young people is a doctoral student at Johns Hopkins, Andrew Wong. Mr Wong is a Ph.D. student studying materials science and engineering. Along with his facility advisor he has [...]
The good news for us is that the survival of men diagnosed with prostate cancer has improved over time. The current 10-year relative survival rate is 99.7%! However, the long survival of men who have prostate cancer raises questions about their risk of a second primary cancer and the need for continued surveillance. A very [...]
